1. Natural alkaloid bouchardatine ameliorates metabolic disorders in high‐fat diet‐fed mice by stimulating the sirtuin 1/liver kinase B‐1/AMPK axis
- Author
-
Rao, Yong, Yu, Hong, Gao, Lin, Lu, Yu‐Ting, Xu, Zhao, Liu, Hong, Gu, Lian‐Quan, Ye, Ji‐Ming, and Huang, Zhi‐Shu
- Subjects
Male ,Biological Products ,Dose-Response Relationship, Drug ,Molecular Structure ,Hep G2 Cells ,AMP-Activated Protein Kinases ,Protein Serine-Threonine Kinases ,Diet, High-Fat ,Research Papers ,Indole Alkaloids ,Mice, Inbred C57BL ,Mice ,Structure-Activity Relationship ,Liver ,Metabolic Diseases ,Sirtuin 1 ,3T3-L1 Cells ,Animals ,Humans - Abstract
Promoting energy metabolism is known to provide therapeutic effects for obesity and associated metabolic disorders. The present study evaluated the therapeutic effects of the newly identified bouchardatine (Bou) on obesity-associated metabolic disorders and the molecular mechanisms of these effects.The molecular mode of action of Bou for its effects on lipid metabolism was first examined in 3T3-L1 adipocytes and HepG2 cells. This was followed by an evaluation of its metabolic effects in mice fed a high-fat diet for 16 weeks with Bou being administered in the last 5 weeks. Further mechanistic investigations were conducted in pertinent organs of the mice and relevant cell models.In 3T3-L1 adipocytes, Bou reduced lipid content and increased sirtuin 1 (SIRT1) activity to facilitate liver kinase B1 (LKB1) activation of AMPK. Chronic administration of Bou (50 mg∙kgBou may have therapeutic potential for obesity-related metabolic diseases by increasing the capacity of energy expenditure in adipose tissues and liver through a mechanism involving the SIRT1-LKB1-AMPK axis.
- Published
- 2017